Rigel Pharma(RIGL.US)

Last Updated 19:00:00 ET
longbridge loading

Rigel Pharmaceuticals shareholders approve amended 2018 equity incentive plan

PUBT·
US
RIGL
+1.84%
PUBT·
US
RIGL
+1.84%

Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference | RIGL Stock News

StockTitan·
US
RIGL
+1.84%
StockTitan·
US
RIGL
+1.84%

<![CDATA[Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu]]>

Pharmexec·
US
LLY
-0.25%
US
RIGL
+1.84%
US
PFE
+0.51%
Pharmexec·
US
LLY
-0.25%
US
RIGL
+1.84%
US
PFE
+0.51%

These Analysts Increase Their Forecasts On Arvinas After Q1 Results

benzinga_article·
US
ARVN
+6.43%
US
PFE
+0.51%
US
RIGL
+1.84%
benzinga_article·
US
ARVN
+6.43%
US
PFE
+0.51%
US
RIGL
+1.84%

Arvinas Buy Rating Reiterated as Analyst Highlights Pipeline Optionality and VEPPANU Deal, Maintains $18 Price Target

Tip Ranks·
US
ARVN
+6.43%
US
RIGL
+1.84%
US
PBE
+1.60%
Tip Ranks·
US
ARVN
+6.43%
US
RIGL
+1.84%
US
PBE
+1.60%

<![CDATA[Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu]]>

Pharmexec·
US
ARVN
+6.43%
US
RIGL
+1.84%
US
PFE
+0.51%
Pharmexec·
US
ARVN
+6.43%
US
RIGL
+1.84%
US
PFE
+0.51%

Pfizer PROTAC Licensing Deal With Rigel Adds Royalties To Valuation Story

Simplywall·
US
PFE
+0.51%
US
RIGL
+1.84%
US
ARVN
+6.43%
Simplywall·
US
PFE
+0.51%
US
RIGL
+1.84%
US
ARVN
+6.43%

Rigel Pharma shares are trading higher. The company announced an exclusive, global license agreement with Arvinas and Pfizer to develop, manufacture and commercialize VEPPANU, oral PROteolysis TArgeting Chimera.

benzinga_article·
US
RIGL
+1.84%
US
PFE
+0.51%
US
ARVN
+6.43%
benzinga_article·
US
RIGL
+1.84%
US
PFE
+0.51%
US
ARVN
+6.43%

Analyst Reiterates Buy on Rigel as VEPPANU Acquisition Expands Portfolio; Price Target Maintained at $57

Tip Ranks·
US
RIGL
+1.84%
Tip Ranks·
US
RIGL
+1.84%
© 2026 Longbridge｜Disclaimer